Simplex Trading’s Briacell Therapeutics BCTX Stock Holding History

Simplex Trading’s Portfolio BCTX Stock Details BCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1	Closed	-$1K	–	8838
2023 Q4	$1K	Buy	+1	New	+$718	﹤0.01%	8433

Other funds holding BCTX

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CWP

Concord Wealth Partners Abingdon, Virginia $770M AUM 18.25% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $33.7B AUM 35.49% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HWA

HHM Wealth Advisors Chattanooga, Tennessee $996M AUM 23.11% 1-Year Est. Return

Simplex Trading's BCTX Position: Q4 2024 in Review

Simplex Trading sold out of Briacell Therapeutics (BCTX) in Q4 2024, closing a stake of 2 shares — an estimated $240 sold.

Simplex Trading first reported a position in BCTX in Q4 2021 and held it in 8 quarters. The position peaked at $260K in Q1 2022. 25 funds tracked by Wall St. Rank hold BCTX as of Q4 2024.

Simplex Trading reported no remaining Briacell Therapeutics position as of Q4 2024 after selling out during the quarter.
Simplex Trading sold 2 Briacell Therapeutics shares in Q4 2024, an estimated $240.
Simplex Trading first reported a position in Briacell Therapeutics in Q4 2021 and held it in 8 quarters.
Simplex Trading's Briacell Therapeutics position peaked at $260K in Q1 2022.
25 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q4 2024.

Based on Simplex Trading's 13F filing for Q4 2024, filed 11 Feb 2025.